Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Hormones (Athens). 2023 Mar;22(1):5-11. doi: 10.1007/s42000-022-00405-7. Epub 2022 Oct 21.
To compare the kinetics of neutralizing antibodies (NΑbs) against SARS-CoV-2 after vaccination with the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech) between patients with T2DM and healthy controls.
NAb levels after the BNT162b2 mRNA vaccine were compared between 50 patients with non-insulin treated T2DM and 50 age-, gender-, and BMI-matched healthy controls up to 3 months after the second dose. The median age of both groups was 70 years.
On day 1, mean NAbs of the control and T2DM groups were 14.64% (standard error, SE = 2.30) and 14.04% (SE = 2.14), respectively (p value = 0.926). Three weeks later, the mean NAb values were 39.98% (SE = 3.53) in the control group and 40.97% (SE = 3.99) in participants with T2DM (p value = 0.698). One month after the second vaccination, mean NAb values increased to 87.13% (SE = 2.94) in the control group and 89.00% (SE = 2.18) in the T2DM group. Three months after the second vaccine dose, the mean inhibitory titers decreased to 83.49% (SE = 3.82) (control group) and 76.36% (SE = 3.33) (T2DM group). On all occasions, no significant difference was found between the two groups (all p values > 0.05).
Patients with T2DM present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to that of healthy subjects.
比较 T2DM 患者与健康对照者接种 BNT162b2 mRNA 疫苗（辉瑞/BioNTech 公司的 Comirnaty）后针对 SARS-CoV-2 的中和抗体（NAb）动力学。
在第二次接种后 3 个月内，比较了 50 例未经胰岛素治疗的 T2DM 患者和 50 例年龄、性别和 BMI 匹配的健康对照者在 BNT162b2 mRNA 疫苗接种后的 NAb 水平。两组的中位年龄均为 70 岁。
第 1 天，对照组和 T2DM 组的平均 NAb 分别为 14.64%（标准误差，SE=2.30）和 14.04%（SE=2.14）（p 值=0.926）。3 周后，对照组的平均 NAb 值为 39.98%（SE=3.53），T2DM 组为 40.97%（SE=3.99）（p 值=0.698）。第二次接种后 1 个月，对照组的平均 NAb 值增加至 87.13%（SE=2.94），T2DM 组为 89.00%（SE=2.18）。第二次接种后 3 个月，平均抑制滴度下降至对照组 83.49%（SE=3.82）和 T2DM 组 76.36%（SE=3.33）。在所有情况下，两组之间均未发现显著差异（所有 p 值均>0.05）。
T2DM 患者对 COVID-19 BNT162b2 mRNA 疫苗的免疫反应与健康受试者相似。
